Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LAURION Intercepts of 37.70 g/t Gold over 0.50 m, 6.60 g/t Gold over 1.00 m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bausch Lomb Ord Shs BLCO


Primary Symbol: T.BLCO

Healthcare Medical Devices
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative... see more

Recent & Breaking News (TSX:BLCO)

Bausch + Lomb and Sanoculis Announce Strategic Agreements Designed to Address Unmet Needs in Glaucoma

PR Newswire July 28, 2022

Bausch + Lomb Enrolls First Patient in LASIK Clinical Trial Evaluating Use of Technolas® TENEO(TM) Excimer Laser* for Vision Correction Surgery for Hyperopia with Astigmatism

PR Newswire July 26, 2022

Bausch + Lomb Will Release Second-Quarter 2022 Financial Results on August 4

PR Newswire July 25, 2022

Bausch + Lomb Provides Leadership Update

PR Newswire July 20, 2022

Bausch + Lomb and Novaliq Announce Submission of New Drug Application for Investigational Treatment NOV03 (Perfluorohexyloctane)

PR Newswire July 7, 2022

Bausch + Lomb Announces Scientific Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) to be Presented During the American Society of Retina Specialists Annual Scientific Meeting

PR Newswire July 6, 2022

Bausch + Lomb Announces Brett Icahn and Gary Hu Have Been Appointed to its Board of Directors

PR Newswire June 23, 2022

Bausch + Lomb Announces the U.S. Launch of Revive(TM) Custom Soft Contact Lenses

PR Newswire June 13, 2022

Bausch + Lomb Announces First-Quarter 2022 Results and Provides 2022 Guidance

PR Newswire June 8, 2022

Bausch + Lomb Announces Scientific Data on Latest Biotrue® Products to be Presented at American Optometric Association's Optometry's Meeting

PR Newswire June 6, 2022

New Social Media Campaign From Bausch + Lomb Aims to Raise Awareness that Cataracts Don't Wait

PR Newswire June 2, 2022

Bausch + Lomb Announces the U.S. Launch of Biotrue® Hydration Plus Multi-Purpose Solution

PR Newswire June 2, 2022

Bausch + Lomb Will Release First-Quarter 2022 Financial Results on June 8

PR Newswire May 25, 2022

Bausch + Lomb Receives Health Canada Approval of LUMIFY® Redness Reliever Eye Drops

PR Newswire May 24, 2022

Bausch + Lomb Corporation Files Financial Statements for the First Quarter of 2022

PR Newswire May 16, 2022

Bausch + Lomb Announces Participation at the RBC Capital Markets Global Healthcare Conference

PR Newswire May 13, 2022

New Survey Shows Retina Specialists Believe Suprachoroidal Administration is an Option for Patients With Macular Edema Associated With Noninfectious Uveitis

PR Newswire May 12, 2022

Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions

PR Newswire May 10, 2022

BAUSCH + LOMB CORPORATION LAUNCHES AS A PUBLICLY TRADED COMPANY

PR Newswire May 6, 2022

IIROC Trade Resumption - BLCO

Canada NewsWire May 6, 2022